Editorial: ondansetron for patients with IBS-D and bowel-predominant symptoms-authors' reply

David Gunn^{1

2}, Alexander Ford^{3

4}, Amanda Farrin⁵, Robin Spiller^{1

2}

Affiliations

¹ NIHR Nottingham Digestive Diseases Biomedical Research Centre, University of Nottingham, Nottingham, UK.
² Nottingham Digestive Diseases Centre, Nottingham University Hospitals NHS Trust, Nottingham, UK.
³ Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK.
⁴ Leeds Gastroenterology Institute, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
⁵ Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.

Editorial

David Gunn et al. Aliment Pharmacol Ther. 2023 Jun.

. 2023 Jun;57(11):1337-1338.

doi: 10.1111/apt.17496.

David Gunn^{1

2}, Alexander Ford^{3

4}, Amanda Farrin⁵, Robin Spiller^{1

2}

¹ NIHR Nottingham Digestive Diseases Biomedical Research Centre, University of Nottingham, Nottingham, UK.
² Nottingham Digestive Diseases Centre, Nottingham University Hospitals NHS Trust, Nottingham, UK.
³ Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK.
⁴ Leeds Gastroenterology Institute, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
⁵ Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.

No abstract available

Comment on

Randomised, placebo-controlled trial and meta-analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: The TRITON trial.
Gunn D, Topan R, Barnard L, Fried R, Holloway I, Brindle R, Corsetti M, Scott M, Farmer A, Kapur K, Sanders D, Eugenicos M, Trudgill N, Whorwell P, Mclaughlin J, Akbar A, Houghton L, Dinning PG, Aziz Q, Ford AC, Farrin AJ, Spiller R. Gunn D, et al. Aliment Pharmacol Ther. 2023 Jun;57(11):1258-1271. doi: 10.1111/apt.17426. Epub 2023 Mar 3. Aliment Pharmacol Ther. 2023. PMID: 36866724
Editorial: ondansetron for patients with IBS-D and bowel-predominant symptoms.
Shah ED. Shah ED. Aliment Pharmacol Ther. 2023 Jun;57(11):1335-1336. doi: 10.1111/apt.17462. Aliment Pharmacol Ther. 2023. PMID: 37161628 No abstract available.

1. Shah E. Editorial: ondansetron for patients with IBS-D and bowel predominant symptoms. Aliment Pharmacol Ther. 2023;57:1335-6.
1. Gunn D, Topan R, Barnard L, Fried R, Holloway I, Brindle R, et al. Randomised, placebo-controlled trial and meta-analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: the TRITON trial. Aliment Pharmacol Ther. 2023;57:1258-71. https://doi.org/10.1111/apt.17426
1. Garsed K, Chernova J, Hastings M, Lam C, Marciani L, Singh G, et al. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut. 2014;63(10):1617-25. https://doi.org/10.1136/gutjnl-2013-305989
1. Chey WY, Jin HO, Lee MH, Sun SW, Lee KY. Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea. Am J Gastroenterol. 2001;96(5):1499-506.
1. Bampton PA, dinning p, Kennedy ML, et al. Spatial and temporal organization of pressure patterns throughout the unprepared colon during spontaneous defecation. Am J Gastroenterol. 2000;95(4):1027-35.